Iparomlimab and Tuvonralimab

Phase 3Monoclonal antibody

Iparomlimab and Tuvonralimab is one of 513 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

512

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaNot yet recruiting

Nasopharyngeal CarcinomaNot yet recruiting

AdenocarcinomaRecruiting

Metastatic Colorectal CancerRecruiting

Breast CancerNot yet recruiting

Colorectal CancerNot yet recruiting

Ovarian CancerNot yet recruiting

Hepatocellular CarcinomaRecruiting

Gastric CancerRecruiting

Endometrial CancerNot yet recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Not yet recruiting

Nasopharyngeal CarcinomaPhase 2

Not yet recruiting

AdenocarcinomaPhase 2

Recruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Breast CancerPhase 2

Not yet recruiting

Colorectal CancerPhase 2

Not yet recruiting

Ovarian CancerPhase 2

Not yet recruiting

Hepatocellular CarcinomaPhase 2

Recruiting

Gastric CancerPhase 2

Recruiting

Endometrial CancerPhase 2

Not yet recruiting

Showing 10 of 25 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Iparomlimab and Tuvonralimab

Qilu Pharmaceutical Co., Ltd.

Phase 3

2 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT07014150

Q3 2027

Phase 2Not yet recruiting

Ovarian Cancer

NCT07117877

Phase 1/2Recruiting

Immunotherapy

NCT07291947

Q4 2027

Phase 2Recruiting

Adenocarcinoma

NCT06932068

Q1 2028

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT07349225

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma4 trials

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

Recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT07327788·38 enrolled

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07131501·48 enrolled

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07014150·30 enrolled

Show 1 more trial

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Not yet recruiting·—·Phase 2·NCT07128251·47 enrolled

Ovarian Cancer2 trials

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07407452·50 enrolled

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07117877·33 enrolled

Radiotherapy2 trials

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Recruiting·—·Phase 2·NCT07165847·40 enrolled

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not yet recruiting·—·Phase 2·NCT07116577·37 enrolled

Gastric Cancer2 trials

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT07392346·68 enrolled

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07289997·39 enrolled

Small Cell Lung Cancer2 trials

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Not yet recruiting·TThe Second Affiliated Hospital of Dalian Medical University·Phase 2·NCT07349225·46 enrolled

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06789796·636 enrolled

24 more indications

Breast Cancer2 trials

Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Not yet recruiting·RRenJi Hospital·Phase 2·NCT07396324·55 enrolled

Efficacy and Safety of QL1706 Combined With Neoadjuvant Endocrine Therapy in Patients With HR-Positive/HER2-Negative Breast Cancer Showing a Poor Response to Neoadjuvant Chemotherapy: A Prospective, Randomized Controlled Clinical Trial

Not yet recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07782840·40 enrolled

Tuvonralimab1 trial

Iparomlimab and Tuvonralimab in HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07090317·30 enrolled

Adenocarcinoma1 trial

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Recruiting·QQilu Hospital of Shandong University·Phase 2·NCT06932068·77 enrolled

Metastatic Colorectal Cancer1 trial

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07150247·20 enrolled

Colorectal Cancer1 trial

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07446387·70 enrolled

First-line Treatment1 trial

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07383285·106 enrolled

Cervical Cancer1 trial

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06942416·36 enrolled

Recurrent or Metastatic NPC1 trial

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Recruiting·SSun Yat-sen University·Phase 2·NCT07101744·41 enrolled

Gastroesophageal Junction Cancer1 trial

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Recruiting·—·Phase 2·NCT07315854·32 enrolled

Neoadjuvant1 trial

Neoadjuvant QL1706 Therapy for ESCC

Recruiting·SShandong Provincial Hospital·Phase 2·NCT06908382·32 enrolled

Esophageal Squamous Cell Carcinoma1 trial

QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06852456·30 enrolled

Endometrial Cancer1 trial

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Not yet recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2·NCT07369986·30 enrolled

Chemoradiotherapy1 trial

Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT07041788·25 enrolled

Nasopharyngeal Carcinoma1 trial

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT07135804·45 enrolled

Immunotherapy1 trial

PULSAR Combined With Immunotherapy and Chemotherapy

Recruiting·WWang Xin·Phase 1/2·NCT07291947·60 enrolled

Hypofractionated Radiotherapy1 trial

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07447570·27 enrolled

Hepatocellular Carcinoma (HCC)1 trial

Effectiveness and Safety of Stereotactic Body Radiotherapy Combined With Iparomlimab and Tuvonralimab and Bevacizumab in Patients With Locally Advanced or Oligometastatic Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center Study

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07882056·33 enrolled

Gastric Adenocarcinoma1 trial

Iparomlimab and Tuvonralimab in Combination With Albumin-Bound Paclitaxel, Oxaliplatin, and S-1 as Neoadjuvant Therapy for Locally Advanced Gastric or Gastroesophageal Junction Cancer: A Single-center, Single-arm, Prospective, Open-label, Phase 2 Clinical Study

Recruiting·RRuijin Hospital·Phase 2·NCT07867392·28 enrolled

Melanoma (Skin)1 trial

The Efficacy and Safety of Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial (Cryo-IA-Check-002)

Recruiting·SSun Yat-sen University·Phase 2·NCT07847359·28 enrolled

Resectable Hepatocellular Carcinoma With High Risk of Recurrence1 trial

A Prospective, Open-Label, Single-Arm, Exploratory Clinical Study on the Anti-Recurrence Effect of Neoadjuvant Iparomlimab and Tuvonralimab in Resectable Hepatocellular Carcinoma With High Risk of Recurrence After Radical Resection

Recruiting·TTongji Hospital·Phase 2·NCT06954116·26 enrolled

HCC - Hepatocellular Carcinoma1 trial

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Lenvatinib, Radiotherapy, and Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07776080·35 enrolled

Gastric / Gastroesophageal Junction Adenocarcinoma1 trial

A Randomized, Controlled, Multi-centers, Non Inferiority Phase II Clinical Study Comparing Iparomlimab and Tuvonralimab With Standard Chemotherapy Combined With PD-1/PD-L1 Monoclonal Antibody as First-line Treatment for MSI-H/dMMR Recurrent/Metastatic Gastric Cancer

Recruiting·PPeking University·Phase 2·NCT07127822·106 enrolled

Colon Cancer1 trial

Efficacy and Safety of Conversion Therapy for pMMR/MSS T4M0 Colon Cancer Patients Treated With Radiotherapy and Systemic Therapy: a Prospective, Open-label, Multi-center, Randomized Controlled Trial（Neo-Color）

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06949111·128 enrolled

Biliary Tract Cancer (BTC)1 trial

A Multicenter, Single-Arm, Phase II Clinical Study of QL1706 in Combination With Gemcitabine and Cisplatin (GC) as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer

Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07733115·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Iparomlimab and Tuvonralimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iparomlimab and Tuvonralimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iparomlimab and Tuvonralimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Qilu Pharmaceutical Co., Ltd.

Iparomlimab and Tuvonralimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Hepatocellular Carcinoma4 trials

Ovarian Cancer2 trials

Radiotherapy2 trials

Gastric Cancer2 trials

Small Cell Lung Cancer2 trials

Breast Cancer2 trials

Tuvonralimab1 trial

Adenocarcinoma1 trial

Metastatic Colorectal Cancer1 trial

Colorectal Cancer1 trial

First-line Treatment1 trial

Cervical Cancer1 trial

Recurrent or Metastatic NPC1 trial

Gastroesophageal Junction Cancer1 trial

Neoadjuvant1 trial

Esophageal Squamous Cell Carcinoma1 trial

Endometrial Cancer1 trial

Chemoradiotherapy1 trial

Nasopharyngeal Carcinoma1 trial

Immunotherapy1 trial

Hypofractionated Radiotherapy1 trial

Hepatocellular Carcinoma (HCC)1 trial

Gastric Adenocarcinoma1 trial

Melanoma (Skin)1 trial

Resectable Hepatocellular Carcinoma With High Risk of Recurrence1 trial

HCC - Hepatocellular Carcinoma1 trial

Gastric / Gastroesophageal Junction Adenocarcinoma1 trial

Colon Cancer1 trial

Biliary Tract Cancer (BTC)1 trial

References

Drug Info

Quick Facts

Related News